CEO Jean Engela meets investors and collaborators in San Francisco from January 12 to 15, 2026.
Tacalyx is in San Francisco for JPM Week 2026, January 12–15.
"This is the flagship healthcare event of the year and I'm looking forward to engaging investors and collaborators. We have a series of updates to share and opportunities to discuss."
— Jean Engela, CEO
Press releases
€11 million from the existing syndicate in a first closing of the seed extension. TCX-201 is selected as first clinical candidate, with a CTA filing planned for 2027.
Scientific presentations
Two posters at the AACR Annual Meeting 2026 in San Diego: the preclinical profile of first clinical candidate TCX-201 (Poster 5631) and TCX-101 as a trispecific T-cell engager (Poster 5584).
Company
Scientific Advisory Board meeting in Berlin, Clinical Advisory Board meeting and AACR Oncology Industry Partnering Event in San Diego, followed by two posters at AACR 2026.